WO2006122925A3 - Medicament oral a base d'inhibiteur de pompe a protons - Google Patents

Medicament oral a base d'inhibiteur de pompe a protons Download PDF

Info

Publication number
WO2006122925A3
WO2006122925A3 PCT/EP2006/062321 EP2006062321W WO2006122925A3 WO 2006122925 A3 WO2006122925 A3 WO 2006122925A3 EP 2006062321 W EP2006062321 W EP 2006062321W WO 2006122925 A3 WO2006122925 A3 WO 2006122925A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
oral
gastric
ppi
proton pump
Prior art date
Application number
PCT/EP2006/062321
Other languages
English (en)
Other versions
WO2006122925A2 (fr
Inventor
Philippe Caisse
Catherine Castan
Remi Meyrueix
Gerard Soula
Original Assignee
Flamel Tech Sa
Philippe Caisse
Catherine Castan
Remi Meyrueix
Gerard Soula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006122925(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Flamel Tech Sa, Philippe Caisse, Catherine Castan, Remi Meyrueix, Gerard Soula filed Critical Flamel Tech Sa
Priority to CA002608185A priority Critical patent/CA2608185A1/fr
Priority to US11/920,278 priority patent/US20100068291A1/en
Priority to JP2008510598A priority patent/JP5300469B2/ja
Priority to EP06755198A priority patent/EP1879559A2/fr
Publication of WO2006122925A2 publication Critical patent/WO2006122925A2/fr
Publication of WO2006122925A3 publication Critical patent/WO2006122925A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des médicaments oraux à libération modifiée d'IPP, plus particulièrement utiles pour la prévention et le traitement des troubles gastro- intestinaux. Le but de l'invention est de fournir un nouveau médicament oral à base de d' IPP présentant idéalement tout ou partie des caractéristiques suivantes : a) Soulager rapidement le patient par une élévation du pH gastrique, après la prise orale du médicament, b) Accélérer la guérison des patients en maintenant cette élévation du pH gastrique, le plus longtemps possible, après la prise orale du médicament, et en particulier durant la nuit, c) Améliorer l'observance du traitement et le confort du patient par une prise journalière unique. Pour atteindre ce but, les microcapsules de l'invention, de préférence non entériques, sont constituées de microparticules d'IPP enrobées par de l' éthylcellulose, un copolymère ammonio-methacrylate (Eudragit® RL 100) , de la polyvinylpyrrolidone, de l'huile de ricin et de l'huile de ricin hydrogénée polyoxyéthylénée (40) . Ce médicament est conçu de telle sorte qu'après son ingestion pour une administration en une prise journalière unique, il permet de maintenir, dès le premier jour du traitement, un pH gastrique moyen entre 0 et 24h, supérieur ou égal au pH gastrique moyen entre 0 et 24h obtenu avec un médicament oral entérique à libération immédiate de référence*, administré dans les mêmes conditions. L'invention vise également ces microcapsules per se.
PCT/EP2006/062321 2005-05-13 2006-05-15 Medicament oral a base d'inhibiteur de pompe a protons WO2006122925A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002608185A CA2608185A1 (fr) 2005-05-13 2006-05-15 Medicament oral a base d'inhibiteur de pompe a protons
US11/920,278 US20100068291A1 (en) 2005-05-13 2006-05-15 Oral Medicament Based on a Proton Pump Inhibitor
JP2008510598A JP5300469B2 (ja) 2005-05-13 2006-05-15 プロトンポンプインヒビターに基づく経口薬
EP06755198A EP1879559A2 (fr) 2005-05-13 2006-05-15 Medicament oral a base d'inhibiteur de pompe a protons

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0551259A FR2885526B1 (fr) 2005-05-13 2005-05-13 Medicament oral a base d'inhibiteur de pompe a protons
FR05/51259 2005-05-13

Publications (2)

Publication Number Publication Date
WO2006122925A2 WO2006122925A2 (fr) 2006-11-23
WO2006122925A3 true WO2006122925A3 (fr) 2007-02-15

Family

ID=35431213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/062321 WO2006122925A2 (fr) 2005-05-13 2006-05-15 Medicament oral a base d'inhibiteur de pompe a protons

Country Status (7)

Country Link
US (1) US20100068291A1 (fr)
EP (1) EP1879559A2 (fr)
JP (1) JP5300469B2 (fr)
CN (1) CN101208078A (fr)
CA (1) CA2608185A1 (fr)
FR (1) FR2885526B1 (fr)
WO (1) WO2006122925A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153062A (en) * 2007-10-12 2014-12-31 Takeda Pharmaceuticals Usa Inc Methods of treating gastrointestinal disorders independent of the intake of food
PE20141034A1 (es) 2008-03-11 2014-09-10 Takeda Pharmaceutical Preparacion solida de desintegracion oral
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
RU2016147009A (ru) 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Композиции с пролонгированным высвобождением в виде суспензии
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102484953B1 (ko) * 2020-06-25 2023-01-06 주식회사 인트로바이오파마 파모티딘, 수산화마그네슘, 및 침강탄산칼슘을 유효성분으로 하는 위장질환 치료용 필름코팅정제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045321A (en) * 1986-02-13 1991-09-03 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition and its production
EP0709087A1 (fr) * 1994-10-18 1996-05-01 FLAMEL TECHNOLOGIES, Société Anonyme Microcapsules médicamenteuses et/ou nutritionnelles pour administration per os
EP0793959A1 (fr) * 1996-03-07 1997-09-10 Takeda Chemical Industries, Ltd. Composition à libération contrÔlée
WO2000078293A1 (fr) * 1999-06-22 2000-12-28 Astrazeneca Ab Nouvelle formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19606151C2 (de) * 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
ATE541564T1 (de) * 2000-12-07 2012-02-15 Nycomed Gmbh Schnell zerfallende tablette mit einem säurelabilen wirkstoff
JP2004530676A (ja) * 2001-04-18 2004-10-07 ノストラム・ファーマスーティカルズ・インコーポレイテッド 持続放出性薬学的組成物のための新規コーティング
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045321A (en) * 1986-02-13 1991-09-03 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition and its production
EP0709087A1 (fr) * 1994-10-18 1996-05-01 FLAMEL TECHNOLOGIES, Société Anonyme Microcapsules médicamenteuses et/ou nutritionnelles pour administration per os
EP0793959A1 (fr) * 1996-03-07 1997-09-10 Takeda Chemical Industries, Ltd. Composition à libération contrÔlée
WO2000078293A1 (fr) * 1999-06-22 2000-12-28 Astrazeneca Ab Nouvelle formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US9238029B2 (en) 2004-06-16 2016-01-19 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form

Also Published As

Publication number Publication date
US20100068291A1 (en) 2010-03-18
JP5300469B2 (ja) 2013-09-25
FR2885526B1 (fr) 2007-07-27
WO2006122925A2 (fr) 2006-11-23
CN101208078A (zh) 2008-06-25
CA2608185A1 (fr) 2006-11-23
FR2885526A1 (fr) 2006-11-17
JP2009537455A (ja) 2009-10-29
EP1879559A2 (fr) 2008-01-23

Similar Documents

Publication Publication Date Title
WO2006122925A3 (fr) Medicament oral a base d'inhibiteur de pompe a protons
CA2563058C (fr) Traitement de soutien d'une maladie du foie
AU2008267058C1 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
CA2574450A1 (fr) Methode pour traiter l'hyperphosphatemie au moyen d'hydroxycarbonate de lanthane
WO2008027557A3 (fr) Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité
SG170119A1 (en) Nutritional composition comprising indigestible oligosaccharides
HK1115308A1 (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
WO2001015673A3 (fr) Formulations pharmaceutiques et utilisations de ces dernieres pour prevenir l'accident cerebrovasculaire, le diabete et/ou l'insuffisance cardiaque globale
JP2000515486A (ja) アダマンタン誘導体の内耳炎治療向け使用
CA2648126A1 (fr) Traitements a la citrulline
CA2486859A1 (fr) Association de formes posologiques de levodopa/carbidopa a liberation immediate et controlee
JP2005528430A5 (fr)
JP2020522487A (ja) ストレス障害のホルモンカスケードを調節する組成物および方法
TW200616644A (en) Medicine for prevention or treatment of diabetes
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
CA2456604A1 (fr) Composition pharmaceutique comprenant du lumiracoxib
JP2015517994A5 (fr)
CA2416771A1 (fr) Acide 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetique pour le traitement de troubles relies au cox-2
WO2022026622A3 (fr) Traitement de maladies virales
CA2344910A1 (fr) Methode et composition pharmaceutique pour le traitement des maladies renales
WO2005056520A8 (fr) Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie
CA2469702A1 (fr) Utilisation de la darifenacine dans le traitement de mictions imperieuses induites par une vessie hyperactive
CA2506993A1 (fr) Utilisation de l'acide docosahexaenoique en tant que substance active pour le traitement de la lipodystrophie
TR200103665T2 (tr) Nöro ve -retino-koruyucu oftalmolojik ilaçlar
US20170296499A1 (en) Combinational compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006755198

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2608185

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008510598

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 8910/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200680022745.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006755198

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11920278

Country of ref document: US